Seoul Pharma Co. Ltd (018680) — Working Capital to Net Assets Ratio
Seoul Pharma Co. Ltd (018680) has a Working Capital to Net Assets ratio of 46.7% as of September 2025. Working capital of ₩19.30 Billion (current assets of ₩35.76 Billion minus current liabilities of ₩16.46 Billion) is measured against net assets of ₩41.30 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Seoul Pharma Co. Ltd net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Seoul Pharma Co. Ltd Working Capital to Net Assets (2012–2024)
This chart shows how Seoul Pharma Co. Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at 46.7%, reflecting working capital of ₩19.30 Billion against net assets of ₩41.30 Billion KRW. Check Seoul Pharma Co. Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Seoul Pharma Co. Ltd (2012–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Seoul Pharma Co. Ltd from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Seoul Pharma Co. Ltd.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 45.1% | ₩18.12 Billion | ₩40.17 Billion | ₩32.26 Billion | ₩14.14 Billion | ▲ +31.9 pp |
| 2023 | 13.2% | ₩5.08 Billion | ₩38.56 Billion | ₩25.61 Billion | ₩20.53 Billion | ▼ -21.1 pp |
| 2022 | 34.2% | ₩12.12 Billion | ₩35.42 Billion | ₩26.01 Billion | ₩13.89 Billion | ▲ +55.3 pp |
| 2021 | -21.1% | ₩-3.99 Billion | ₩18.96 Billion | ₩24.81 Billion | ₩28.80 Billion | ▼ -47.0 pp |
| 2020 | 25.9% | ₩7.49 Billion | ₩28.85 Billion | ₩25.93 Billion | ₩18.45 Billion | ▲ +31.3 pp |
| 2019 | -5.3% | ₩-1.51 Billion | ₩28.45 Billion | ₩25.22 Billion | ₩26.73 Billion | ▼ -65.1 pp |
| 2018 | 59.8% | ₩30.09 Billion | ₩50.31 Billion | ₩44.11 Billion | ₩14.02 Billion | ▲ +18.8 pp |
| 2017 | 41.0% | ₩22.07 Billion | ₩53.86 Billion | ₩40.51 Billion | ₩18.44 Billion | ▼ -19.5 pp |
| 2016 | 60.4% | ₩25.43 Billion | ₩42.07 Billion | ₩37.38 Billion | ₩11.95 Billion | ▲ +42.1 pp |
| 2015 | 18.3% | ₩6.14 Billion | ₩33.53 Billion | ₩30.02 Billion | ₩23.88 Billion | ▲ +10.7 pp |
| 2014 | 7.6% | ₩2.38 Billion | ₩31.10 Billion | ₩24.78 Billion | ₩22.40 Billion | ▼ -3.7 pp |
| 2013 | 11.3% | ₩3.66 Billion | ₩32.25 Billion | ₩19.97 Billion | ₩16.31 Billion | ▼ -9.7 pp |
| 2012 | 21.1% | ₩5.35 Billion | ₩25.38 Billion | ₩18.73 Billion | ₩13.38 Billion | — |